Wegovy In India
-
{
- All
- News
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
Ozempic Launched In India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been launched in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Prices
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
Wegovy And Mounjaro For Weight Loss Are In, But India Wants A No-Drug Obesity Fix
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications
-
Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
Ozempic Launched In India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been launched in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Prices
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
Wegovy And Mounjaro For Weight Loss Are In, But India Wants A No-Drug Obesity Fix
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications
-
Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.
